Natural Antioxidant in Cardiovascular and Cerebrovascular Diseases

Jung, Yi-Sook

doi:10.3390/antiox11061159

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CVD is known to cause neurodegeneration and mimic AD pathology. Various natural compounds, such as sinapic acid, auraptene, 4,60-anhydrooxysporidinone [ 6 ], rosmarinic acid [ 7 ], taurine [ 8 ], and epigallocatechin [ 9 ], are known to attenuate CVD and AD by improving BBB function and maintaining BBB integrity [ 9 , 10 ]. AST is a xanthophyll carotenoid, and is found in various microorganisms ( Paracoccus carotinifaciens ), microalgae ( Haematococcus species; genus of Chlorophycecae ), yeast ( Xanthophyllomyces dendrorhous ), and marine animals, such as salmon (genus Oncorhynchus ; Salmo salar ), shrimp ( Penaeus semisulcatus ), krill ( Euphausia pacifica ), and crayfish [ 11 , 12 , 13 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Astaxanthin: A Marine Drug That Ameliorates Cerebrovascular-Damage-Associated Alzheimer’s Disease in a Zebrafish Model via the Inhibition of Matrix Metalloprotease-13

Paramakrishnan,

Lim,

Paramaswaran

et al. 2023

Marine Drugs

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a major type of dementia disorder. Common cognitive changes occur as a result of cerebrovascular damage (CVD) via the disruption of matrix metalloproteinase-13 (MMP-13). In diabetic cases, the progress of vascular dementia is faster and the AD rate is higher. Patients with type 2 diabetes are known to have a higher risk of the factor for AD progression. Hence, this study is designed to investigate the role of astaxanthin (AST) in CVD-associated AD in zebrafish via the inhibition of MMP-13 activity. CVD was developed through the intraperitoneal and intracerebral injection of streptozotocin (STZ). The AST (10 and 20 mg/L), donepezil (1 mg/L), and MMP-13 inhibitor (i.e., CL-82198; 10 μM) were exposed for 21 consecutive days in CVD animals. The cognitive changes in zebrafish were evaluated through light and dark chamber tests, a color recognition test, and a T-maze test. The biomarkers of AD pathology were assessed via the estimation of the cerebral extravasation of Evans blue, tissue nitrite, amyloid beta-peptide aggregation, MMP-13 activity, and acetylcholinesterase activity. The results revealed that exposure to AST leads to ameliorative behavioral and biochemical changes. Hence, AST can be used for the management of AD due to its multi-targeted actions, including MMP-13 inhibition.

show abstract

Section: Introductionmentioning

confidence: 99%

Astaxanthin: A Marine Drug That Ameliorates Cerebrovascular-Damage-Associated Alzheimer’s Disease in a Zebrafish Model via the Inhibition of Matrix Metalloprotease-13

Paramakrishnan,

Lim,

Paramaswaran

et al. 2023

Marine Drugs

View full text Add to dashboard Cite

show abstract

Diabetic retinopathy: New concepts of screening, monitoring, and interventions

Sinclair,

Schwartz

2024

Survey of Ophthalmology

View full text Add to dashboard Cite

Stop Ischemic Event to the Brain

Yang,

Zhang,

Nie

et al. 2024

The Neurologist

View full text Add to dashboard Cite

Objectives: In this study, we investigated the difference in risk factors between the 2 diseases, aiming to further clarify who needs to do ischemic cerebrovascular disease (ICVD)-related screening among coronary artery disease (CAD) patients. Methods: Clinical data of 326 patients with first-episode CAD from June 1, 2017, to July 31, 2020, in the Chinese PLA General Hospital were retrospectively reviewed. Outcomes, including clinical features and laboratory examination, were taken. Features related to ICVD including the extension of intracranial arterial (internal carotid artery intracranial segment, middle cerebral artery M1 segment, anterior cerebral A1 segment, vertebrobasilar artery intracranial segment, posterior cerebral artery P1 segment) and carotid arterial (internal carotid artery extracranial segment, common carotid artery, subclavian artery) stenosis were detected. Risk factors for the occurrence of ICVD in patients with CAD were analyzed. Results: Among patients with the onset of CAD, in comparison of the nonstenosis and stenosis of intracranial artery subgroups, there were statistical differences in the onset age, hypertension, and duration of hypertension as well as the biochemical indicators, including high-density lipoprotein and glycosylated hemoglobin. In addition, statistical differences were detected in the onset age as well as the biochemical indicators, including glycosylated hemoglobin and blood glucose serum protein, along with the difference in the degree of cardiovascular stenosis. Conclusions: The onset age of CAD was shown to serve as a vital risk factor for ICVD. The primary prevention of ICVD in patients with CAD should lay more emphasis on the management of hypertension and diabetes.

show abstract

Natural Antioxidant in Cardiovascular and Cerebrovascular Diseases

Abstract: Cardiovascular (CVD) and cerebrovascular diseases, with 17.9 million and 2 million deaths every year, respectively, are the leading cause of death worldwide [1,2] [...]

Cited by 3 publications

References 17 publications

Astaxanthin: A Marine Drug That Ameliorates Cerebrovascular-Damage-Associated Alzheimer’s Disease in a Zebrafish Model via the Inhibition of Matrix Metalloprotease-13

Astaxanthin: A Marine Drug That Ameliorates Cerebrovascular-Damage-Associated Alzheimer’s Disease in a Zebrafish Model via the Inhibition of Matrix Metalloprotease-13

Diabetic retinopathy: New concepts of screening, monitoring, and interventions

Stop Ischemic Event to the Brain

Contact Info

Product

Resources

About